CARDISTM Platform – Discover and optimize ScFv-based CARs to surface-expressed antigens
-
Hybrid of phage & proprietary mammalian display platforms
-
Direct functional selection from pooled library – more & better hits
-
Fully human ScFv libraries – lower risk of immunogenicity
T Cell Receptor (TCR) therapies represent the next generation opportunity to empower immune effector cells for ACT. TCRs recognize components of tumor-specific proteins from inside of cells in a different way than antibodies and, therefore, require precise characterization and, in many cases, engineering. ACTs utilizing TCRs widen the scope of tumor targets beyond CAR-based approaches, and in addition, TCR and CAR ACT approaches offer complementary ways to treat cancer.
T-RxTM Platform – Discover and optimize TCRs to intracellular antigens
-
Based on proprietary mammalian display platform
-
Direct functional selection from pooled library – more & better hits
-
TCRs from natural donors – leverage natural thymic selection
-
De novo TCR discovery – any HLA, any presented peptide
-
Extensive proprietary off-target profiling
Learn about how immune effector cells are genetically engineered with CARs to produce a targeting receptor enabling them to act as a living drugs against cancer cells.
T Cell Receptor (TCR) Technology
Learn more about how immune effector cells are genetically engineered with our TCR’s and activated as a living drug to generate an immune response against cancer